Synopsis: Acemannan-rich Aloe polysaccharides can enhance drug performance by reversibly opening intestinal tight junctions and possibly modulating P-glycoprotein, improving paracellular absorption and mucosal delivery of poorly absorbed hydrophilic drugs when dose and formulation are carefully controlled.

Acemannan-rich Aloe polysaccharides have been characterized as promising natural absorption enhancers that can transiently loosen intestinal tight junctions and interact with efflux systems such as P-glycoprotein, thereby improving the oral performance of certain poorly absorbed drugs when used under carefully controlled conditions.

Acemannan-rich Aloe polysaccharides show intestinal drug absorption–enhancing activity in vitro and ex vivo, particularly in Caco-2 and intestinal tissue models, where Aloe gel and whole-leaf fractions increase paracellular transport of hydrophilic macromolecules such as FITC-dextran and peptide drugs (Haasbroek et al., 2019; Chen et al., 2009; Gerber et al., 2020). Confocal microscopy and TEER measurements demonstrate reversible tight-junction modulation associated with F-actin rearrangement and enlarged intercellular spaces rather than frank epithelial damage, supporting a mechanism of controlled opening of the paracellular route (Haasbroek et al., 2019).

Beyond tight-junction effects, Aloe vera juice has been reported to modulate P-glycoprotein function in Caco-2 cells, altering the transport of the model P-gp substrate rhodamine 123 and suggesting that Aloe polysaccharides and co-constituents can influence efflux-mediated drug disposition (Spanakis et al., 2024). In human and experimental systems, co-administration of Aloe preparations with small-molecule actives, including vitamins C and E and insulin analogues, has produced higher apparent bioavailability or transepithelial transport, consistent with a dual contribution from paracellular enhancement and possible efflux modulation (Vinson et al., 2005; Chen et al., 2009; Haasbroek et al., 2019).

From a formulation perspective, these data support positioning acemannan-rich Aloe polysaccharides as natural excipients for oral and intestinal delivery systems targeting poorly absorbed, hydrophilic, and/or P-gp-limited drugs, provided that dose, exposure time, and matrix composition are optimized to maintain reversibility and mucosal safety (Chen et al., 2009; Haasbroek et al., 2019). However, most absorption-enhancement evidence comes from Aloe gel or whole-leaf materials in which acemannan is a major but not isolated component, so acemannan’s contribution should be described as mechanistically plausible and strongly supported rather than definitively proven in clinical pharmacokinetic studies (Sierra-García et al., 2014; Bai et al., 2023).

Source of validity: Scientific

Keywords: Aloe Barbadensis Miller, Aloe vera, Drug absorption enhancement, Transepithelial electrical resistance, In vitro transport

Acemannan Enhances Drug Performance by Modulating Intestinal Absorption

Acemannan-rich Aloe polysaccharides can transiently open intestinal tight junctions and enhance paracellular drug transport in vitro and ex vivo, particularly for small hydrophilic compounds such as atenolol and 4 kDa markers.

In Caco-2 monolayers, Aloe vera gel and whole-leaf extract, in which acemannan is the dominant polysaccharide, rapidly reduce transepithelial electrical resistance (TEER), disrupt the perijunctional F-actin ring, and thereby open tight junctions to increase paracellular transport of a 4 kDa FITC-dextran probe (FD-4) by roughly twofold compared with untreated controls (Haasbroek, 2019). In a complementary ex vivo model using excised rat intestinal tissue, all Aloe leaf materials, including gel, whole-leaf extract, and their precipitated polysaccharide fractions, significantly lowered TEER, confirming their capacity to open epithelial tight junctions (Beneke, 2012). Notably, only the precipitated polysaccharides from dehydrated Aloe vera gel standardized as Daltonmax 700, which are acemannan-rich, produced a statistically significant enhancement of atenolol transport at 2% w/v, with an absorption enhancement ratio close to that of the synthetic surfactant positive control (Beneke, 2012; Peterson, 2008). Together, these findings show that Aloe polysaccharide fractions, with acemannan as a key structural component, act as natural absorption enhancers that transiently and reversibly modulate tight junctions to improve paracellular uptake of small hydrophilic drugs and peptides, while the magnitude of enhancement depends strongly on polysaccharide enrichment, concentration, and the molecular size of the co-administered compound (Haasbroek, 2019; Beneke, 2012; Liu, 2019).

Mechanisms by Which Acemannan Rich Aloe Polysaccharides Improve Oral and TransEpithelial Drug Delivery

Tight junction modulation

Tight-junction modulation appears to be the dominant mechanism by which Aloe-derived polysaccharides enhance transepithelial drug transport, with indirect evidence that Aloe juice can also modulate efflux transporters such as P-glycoprotein.

Tight-junction modulation by Aloe gel and whole-leaf extract

Aloe vera gel and whole-leaf extract rapidly reduce transepithelial electrical resistance (TEER) in Caco-2 monolayers within about 20 minutes, with partial recovery over 120 minutes, indicating a reversible increase in paracellular permeability. Fluorescent FITC-dextran 4 kDa (FD-4) accumulates between adjacent Caco-2 cells in the presence of Aloe gel or whole-leaf extract, visually confirming that paracellular flux is increased during the TEER reduction phase (Haasbroek et al., 2019). Confocal imaging shows redistribution and partial disorganization of the cortical F-actin cytoskeleton following exposure to Aloe preparations, consistent with transient modulation of tight junction–associated actin rings (Haasbroek et al., 2019). Together, these findings support tight-junction opening as the principal mechanism by which Aloe gel and whole-leaf materials enhance hydrophilic macromolecule transport across intestinal-like epithelia (Haasbroek et al., 2019).

In vitro, these permeation-enhancing effects are observed with Aloe gel and whole-leaf extract solutions in the approximate range of 0.5–5% w/v under serum-free conditions, concentrations selected to model pharmaceutical excipient use rather than low-dose, barrier-supportive supplementation (Haasbroek et al., 2019). At low to mid concentrations, TEER reduction by Aloe gel can be comparable in magnitude to that produced by the cationic permeation enhancer N-trimethyl chitosan at 0.5% w/v, although the Aloe-induced effect tends to be more rapidly reversible (Haasbroek et al., 2019). In contrast, increasing Aloe gel concentration can raise solution viscosity and partly attenuate TEER reduction, suggesting that diffusion constraints modulate the net paracellular-enhancing effect (Haasbroek et al., 2019). These data indicate that Aloe-based tight-junction modulation has a relatively narrow concentration window that balances sufficient epithelial interaction with acceptable reversibility and cytocompatibility (Haasbroek et al., 2019).

Role of polysaccharides, including Acemannan

Fractionation studies show that precipitated high-molecular-weight polysaccharides isolated from Aloe vera gel and whole-leaf extracts—chemically enriched in acemannan-type acetylated glucomannans—retain most of the atenolol permeability-enhancing activity in Caco-2 models (Haasbroek et al., 2019). These polysaccharide-rich fractions significantly increase the transport of atenolol, a hydrophilic, poorly absorbed beta-blocker, compared with unfractionated Aloe or small-molecule–dominated fractions, implicating the glucomannan component as a key driver of the absorption-enhancing effect (Haasbroek et al., 2019). Contemporary reviews on Aloe-based excipients highlight Aloe gel polysaccharides as promising intestinal permeation enhancers in oral dosage forms designed for Biopharmaceutics Classification System (BCS) class III and IV drugs, particularly hydrophilic peptides and polar small molecules with low passive permeability (Maher et al., 2016; Haasbroek et al., 2019). Within this context, acemannan-rich Aloe polysaccharides are positioned as multifunctional excipients that can modulate tight junctions, hydrate the mucosal surface, and potentially interact with the mucus layer to prolong residence time (Maher et al., 2016).

Given their high safety margin and polysaccharide nature, Aloe gel–derived glucomannans are being explored as alternatives or complements to classical synthetic permeation enhancers such as medium‑chain fatty acids, bile salts, and cationic polymers (Maher et al., 2016). However, the same tight‑junction–opening properties that benefit oral bioavailability of difficult‑to‑absorb actives also raise formulation questions for chronic nutraceutical use, where barrier support rather than enhanced permeability may be desired. This duality underscores the need to differentiate between pharmaceutical‑grade, high‑dose Aloe polysaccharide systems developed as drug‑delivery excipients and lower‑dose Acemannan‑rich supplements intended to support epithelial integrity and mucosal immunity.

P‑glycoprotein modulation: indirect Aloe‑based evidence

Caco-2 transport studies with digoxin as a probe substrate have evaluated whether Aloe vera juice can influence P-glycoprotein (P-gp)–mediated efflux at the intestinal barrier. Djuv and Nilsen (2008) implemented a stringent Caco-2 quality-control protocol and reported that Aloe vera juice at clinically relevant concentrations (0.00001–1.0 mg/mL) did not significantly inhibit P-gp–mediated transport of digoxin, suggesting minimal interaction with P-gp under those specific conditions (Djuv and Nilsen, 2008). A later thesis by Spanakis and colleagues (2010) also examined Aloe vera juice in Caco-2 models and discussed potential modulation of P-gp function, contributing to the broader hypothesis that complex Aloe matrices might influence efflux transport, although detailed peer-reviewed data remain limited (Spanakis, 2010).

Collectively, these studies imply that Aloe juice, which naturally contains both acemannan-type polysaccharides and a spectrum of low-molecular-weight phytochemicals, is unlikely to be a potent P-gp inhibitor at typical oral exposure levels, but modest, context-dependent modulation of efflux cannot be entirely excluded (Djuv and Nilsen, 2008; Spanakis, 2010). Importantly, acemannan itself has not been quantified or tested in isolation as a P-gp inhibitor, so any efflux-related effects observed for Aloe juice or gel must currently be attributed to the whole matrix rather than to a defined polysaccharide entity (Djuv and Nilsen, 2008). For formulation scientists, this means Aloe-containing matrices may subtly alter the pharmacokinetics of P-gp substrates in ways that depend on concentration, co-formulants, and the specific drug, but robust mechanistic attribution to acemannan awaits targeted transporter studies.

Tight Junction Opening, TEER Changes, and Polysaccharide Fractions in Drug Absorption Enhancement

Benefits

Co-formulation of oral drugs with Acemannan-rich Aloe vera gel or purified polysaccharide fractions has the potential to enhance paracellular drug transport while simultaneously supporting mucosal health, but this approach remains constrained by barrier-integrity risks, strong formulation dependence, and a paucity of human pharmacokinetic data.

Co-formulation with Acemannan-rich Aloe vera gel or precipitated polysaccharides may increase the oral bioavailability of hydrophilic small molecules and selected peptide drugs that rely predominantly on paracellular transport, such as model compounds in the atenolol or fluorescein isothiocyanate–dextran (FD-4) size range (Liu et al., 2019; Liu et al., 2021). By improving epithelial permeability at the tight-junction level, these polysaccharide fractions could allow lower oral doses of such drugs to reach therapeutic plasma concentrations, thereby potentially reducing dose-related systemic adverse effects (Liu et al., 2019). In parallel, Acemannan exhibits wound-healing, anti-inflammatory, antioxidant, and broader immunomodulatory actions on mucosal tissues, suggesting that an appropriately titrated co-formulation might couple absorption enhancement with local barrier repair and immune support at the gastrointestinal surface (Liu et al., 2019).

Tight junction and TEER effects

Aloe-derived polysaccharides, including Acemannan, modulate tight-junction structure and function in a strongly dose- and matrix-dependent manner, with distinct “barrier-support” and “enhancement” regimes observable in transepithelial electrical resistance (TEER) assays (Quezada et al., 2017; Tornero-Martínez et al., 2019; Liu et al., 2019). At low μg/mL concentrations, partially purified Acemannan-enriched fractions have been reported to increase TEER and upregulate tight-junction proteins such as ZO-1 and occludin, consistent with barrier reinforcement rather than opening (Quezada et al., 2017; Tornero-Martínez et al., 2019). In contrast, higher-percentage Aloe gel preparations and certain complex polysaccharide matrices can induce TEER reductions and transient tight-junction loosening, corresponding to an “enhancer mode” that facilitates paracellular drug passage (Quezada et al., 2017; Liu et al., 2019; Liu et al., 2021). This bidirectional behavior implies that fine control of polymer dose, molecular-weight distribution, acetylation pattern, and formulation state (fresh gel, dried gel, isolated polysaccharide) will be critical when rationally designing Acemannan-containing absorption-enhancer systems (Liu et al., 2019).

Risks and limitations

Tight-junction opening by Aloe-derived polysaccharides is inherently non-selective, and any formulation that lowers TEER to facilitate drug uptake may also increase the paracellular permeation of dietary antigens, microbial components, and small toxins, raising concerns about chronic barrier stress and low-grade inflammation if used at high concentrations or long term (Quezada et al., 2017; Liu et al., 2019; Liu et al., 2021). Moreover, the magnitude and direction of TEER change depend not only on polysaccharide concentration but also on exposure time, cell model, pH, and the presence of other gel components such as organic acids and phenolics, making it unsafe to extrapolate one preparation’s safety or efficacy profile to another without direct testing (Quezada et al., 2017; Liu et al., 2019). Human in vivo data specifically evaluating Acemannan as an intestinal drug-absorption enhancer remain very limited; most evidence derives from in vitro Caco-2 or ex vivo mucosal models, so translation into clinical practice will require dedicated pharmacokinetic, tolerability, and long-term safety studies with well-defined Aloe/Acemannan compositions (Liu et al., 2019; Liu et al., 2021).

AMB WELLNESS has developed a proprietary with a unique process isolating Acemannan from Aloe Vera Inner Gel with a high content of Acemannan ranging from 10% up to 25% measured by Nuclear Magnetic Resonance (NMR). Designed for high-end cosmetics, healthcare, and nutraceutical applications, Acetypol™ redefines efficacy, supporting skin hydration, barrier function, immune modulation, and gut health,positioning AMB WELLNESS at the forefront of innovation where scientific precision, purity, and performance meet unmatched effectiveness.Acetypol™ offers a more reliable and scientifically controlled alternative to conventional Aloe products, enabling formulators to achieve reproducible results by treating acetylation, purity, and molecular weight as key quality parameters rather than variable outcomes of processing.Acetypol™ offers a more reliable and scientifically controlled alternative to conventional Aloe products, enabling formulators to achieve reproducible results by treating acetylation, purity, and molecular weight as key quality parameters rather than variable outcomes of processing.Acetypol™ is a highly standardized Aloe vera–derived ingredient enriched to 15–20% acemannan with a high degree of acetylation (DA), controlled molecular weight, and high purity.